Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lipitor Watch: Pfizer Hangs On To Share, But At What Cost?

Executive Summary

As the world enters the seventh week of generic atorvastatin, Pfizer has clearly managed to hang on to more share for the brand than it would have under a more traditional, less aggressive strategy. But there was never anything traditional about Lipitor to begin with, so it remains an open question whether another brand firm could reproduce Pfizer’s success, or even its approach, in the face of an exclusivity loss.


Related Content

Generic Crestor Marks The End Of An Era, Should Quickly Outperform PCSK9s
Big Pharma Lays Off Fewer Sales Reps In 2013
Pfizer Mobile App Includes $4 Copay Card For Lipitor
Plavix Takes A Final Bow, But Will It Go Gracefully?
Post-Lipitor Pfizer Will Have Two Business Models: Innovation And Value
Generic Opportunities In 2012 Diluted By Shared Exclusivities
Lipitor Goes Generic, But First-Filer Ranbaxy’s Approval Leaves Plenty Of Questions In Its Wake
Amid The Lipitor Scuffle, What’s Next For Crestor?
Generic Firms Break Camp; FDA Says “First-To-File” Covers Same-Day ANDAs


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts